Not a drug, food, cosmetic, or medical device
Research Background & Scientific Interest BPC-157 has been the subject of numerous peer-reviewed preclinical studies, the majority conducted in rodent models
Furthermore, the beneficial effects of BPC 157 therapy fully involved recovery of the egr-1-gene-implicated pathology (i.e., cardiovascular, liver, and brain) [3,4,5,6,7,8,9,10,11,12,13,14,16,17,18,19,20,21,22,23,24,27,28,29,30,31,32,34,37,39,40]
KLOW is not an FDA-approved treatment and no published clinical trial has evaluated the four-peptide combination together
Monitoring for symptoms and consulting a healthcare provider is important, especially for older adults or those with liver, kidney, or GI issues
That means 7 injections per week, 30 per month, approximately 84 over a 12-week cycle